Cervical Cancer: Emerging Immune Landscape and Treatment
- PMID: 32884290
- PMCID: PMC7434518
- DOI: 10.2147/OTT.S264312
Cervical Cancer: Emerging Immune Landscape and Treatment
Abstract
Immune cells are essential for defending the body's balance and have increasingly been implicated in controlling tumor growth. In cervical cancer (CC), the immune landscape is extensively connected with human papillomavirus (HPV) status. Recent insights from studies have revealed that as a result of infection with HPV, immune cell populations such as lymphocytes or monocytes change during carcinogenesis. Immune therapy, in particular checkpoint inhibitors, those targeting PD-1 or PD-L1, has shown promising efficacy. This article reviews the immune landscape and immunotherapy of CC.
Keywords: TIL; checkpoint blockade; immune; immune therapy; macrophage.
© 2020 Guo and Hua.
Conflict of interest statement
The authors report no conflicts of interest for this work. This project was supported by funding from the Research and Innovation Project of Shanghai Municipal Education Commission (No. 2019-01-07-00-07-E00050), and the Shanghai Science and Technology Natural Science Foundation (No. 19ZR1406900).
References
-
- Feng-Yi X, Feng X, Long S. Diagnostic accuracy of colposcopically directed biopsy and loop electrosurgical excision procedure for cervical lesions. Reprod Dev Med. 2018;2(3):137–141.
-
- Qing W, Cai-Ying Z, Li-Mei C, et al. Clinical value of human papillomavirus E6/E7 mRNA testing in patients with atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion. Reprod Dev Med. 2018;2(3):157–161.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials